BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,188 | -90.0% | 11,891 | -88.2% | 0.00% | -100.0% |
| Q1 2023 | $842,140 | -54.9% | 100,976 | -37.9% | 0.00% | -25.0% |
| Q4 2022 | $1,866,051 | +107.6% | 162,548 | +127.7% | 0.00% | +100.0% |
| Q3 2022 | $899,000 | -42.0% | 71,374 | -51.3% | 0.00% | 0.0% |
| Q2 2022 | $1,549,000 | -19.3% | 146,446 | +5.6% | 0.00% | 0.0% |
| Q4 2021 | $1,920,000 | +14.0% | 138,644 | +18.3% | 0.00% | 0.0% |
| Q3 2021 | $1,684,000 | +33.9% | 117,185 | -5.3% | 0.00% | 0.0% |
| Q1 2021 | $1,258,000 | -21.8% | 123,699 | -42.7% | 0.00% | -33.3% |
| Q4 2020 | $1,609,000 | +241.6% | 216,025 | +57.7% | 0.00% | +200.0% |
| Q3 2020 | $471,000 | +19.8% | 136,977 | +66.0% | 0.00% | -50.0% |
| Q2 2020 | $393,000 | +1968.4% | 82,525 | +1384.8% | 0.00% | – |
| Q4 2019 | $19,000 | +111.1% | 5,558 | +80.2% | 0.00% | – |
| Q3 2019 | $9,000 | -97.7% | 3,085 | -97.0% | 0.00% | -100.0% |
| Q2 2019 | $395,000 | +1617.4% | 104,290 | +3598.2% | 0.00% | – |
| Q1 2019 | $23,000 | -23.3% | 2,820 | -27.3% | 0.00% | – |
| Q3 2018 | $30,000 | -28.6% | 3,879 | -46.7% | 0.00% | – |
| Q2 2018 | $42,000 | +200.0% | 7,283 | +143.7% | 0.00% | – |
| Q1 2018 | $14,000 | +100.0% | 2,988 | +114.3% | 0.00% | – |
| Q4 2017 | $7,000 | -97.2% | 1,394 | -97.1% | 0.00% | -100.0% |
| Q3 2017 | $248,000 | -69.2% | 47,367 | -50.6% | 0.00% | -77.8% |
| Q1 2017 | $806,000 | +56.8% | 95,908 | +18.1% | 0.01% | +80.0% |
| Q4 2016 | $514,000 | +3112.5% | 81,176 | +2084.5% | 0.01% | – |
| Q3 2016 | $16,000 | -56.8% | 3,716 | -71.2% | 0.00% | – |
| Q2 2016 | $37,000 | +117.6% | 12,897 | +108.8% | 0.00% | – |
| Q1 2016 | $17,000 | -46.9% | 6,178 | +123.0% | 0.00% | – |
| Q3 2015 | $32,000 | -63.6% | 2,770 | -71.5% | 0.00% | -100.0% |
| Q1 2015 | $88,000 | -40.1% | 9,735 | -35.4% | 0.00% | -50.0% |
| Q3 2014 | $147,000 | +110.0% | 15,064 | +128.3% | 0.00% | +100.0% |
| Q1 2014 | $70,000 | -87.1% | 6,599 | -90.7% | 0.00% | -87.5% |
| Q4 2013 | $541,000 | +113.8% | 71,125 | +104.4% | 0.01% | +60.0% |
| Q3 2013 | $253,000 | +1000.0% | 34,805 | +130.2% | 0.01% | +400.0% |
| Q2 2013 | $23,000 | – | 15,119 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |